1 Gisondi P, Conti A, Galdo G, Piaserico S, De Simone C, Girolomoni G. Ustekinumab does not increase body mass index in patients with chronic plaque psoriasis: a prospective cohort study. Br J Dermatol. 2013;168:1124-7. doi:10.1111/bjd.12235.
2 Caraceni A, Hanks G, Kaasa S, Bennett MI, Brunelli C, Cherny N, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol. 2012;13:e58-68. doi:10.1016/S1470-2045(12)70040-2.
3 Poulsen JL, Brock C, Olesen AE, Nilsson M, Drewes AM. Evolving paradigms in the treatment of opioid-induced bowel dysfunction. Therap Adv Gastroenterol. 2015;8:360-72. doi:10.1177/1756283X15589526.
4 Morlion B, Clemens KE, Dunlop W. Quality of life and healthcare resource in patients receiving opioids for chronic pain: a review of the place of oxycodone/naloxone. Clin Drug Investig. 2015; 35:1-11. doi:10.1007/s40261-014-0254-6.
5 Lazzari M, Greco MT, Marcassa C, Finocchi S, Caldarulo C, Corli O. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naive cancer patients: a propensity analysis. Drug Des Devel Ther. 2015;9:5863-72. doi:10.2147/DDDT.S92998.
6 Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol. 2011;106:835-42. doi:10.1038/ajg.2011.30.
7 Wirz S, Wittmann M, Schenk M, Schroeck A, Schaefer N, Mueller M, et al. Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine. Eur J Pain. 2009;13:737-43. doi: 10.1016/j.ejpain.2008.09.005.
8 Cook SF, Lanza L, Zhou X, Sweeney CT, Goss D, Hollis K, et al. Gastrointestinal side effects in chronic opioid users: results from a population-based survey. Aliment Pharmacol Ther. 2008;27:1224-32. doi: 10.1111/j.1365-2036.2008.03689.x.
9 Bell TJ, Panchal SJ, Miaskowski C, Bolge SC, Milanova T, Williamson, R. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10:35-42. doi: 10.1111/j.1526-4637.2008.00495.x
10 Yotoku M, Nakanishi A, Kanematsu M, Sakaguchi N, Hashimoto N, Koyama F, et al. Reduction of opioid side effects by prophylactic measures of palliative care team may result in improved quality of life. J Palliat Med. 2010;1:401-6, doi: 10.1089/jpm.2009.0355.
11 Rosti G, Gatti A, Costantini A, Sabato AF, Zucco F. Opioid-related bowel dysfunction: prevalence and identification of predictive factors in a large sample of Italian patients on chronic treatment. Eur Rev Med Pharmacol Sci. 2010;14:1045-50.
12 Higgins PD, Johanson JF. Epidemiology of constipation in North America: a systematic review. Am J Gastroenterol 2004;99:750-9.
13 Tokoro A, Imai H, Fumita S, Harada T, Noriyuki T, Gamoh M, et al. Incidence of opioid-induced constipation in Japanese patients with cancer pain: A prospective observational cohort study. Cancer Medicine. 2019;8:4883-91.
14 Tuteja AK, Biskupiak J; Stoddard GJ, Lipman, AG. Opioid-induced bowel disorders and narcotic bowel syndrome in patients with chronic non-cancer pain. Newrogastroenterol Motil. 2010;22:424-30. doi: 10.1111/j.1365-2982.2009.01458.x.
15 Clinical Guidelines for Cancer Pain Management Second Edition 2014
16 Clinical Guidelines for Gastrointestinal Symptoms in Cancer Patients ver. 2017
17 Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, et al. Japanese study group for the relief of opioid-induced gastrointestinal dysfunction. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012;28:373-81. doi: 10.1097/ajp.0b013e318237d626.
18 Camilleri M, Drossman DA, Becker G, Webster LR, AN Davies, Mawe GM. Emerging treatments in neurogastroenterology: a multidisciplinary working group consensus statement on opioid-induced constipation. Neurogastroenterol Motil. 2014;26:1386-95. doi:10.1111/nmo.12417.
19 Song X, Wang D, Qu X, Dong N, Teng S. A meta-analysis of naldemedine for the treatment of opioid-induced constipation. Expert Rev Clin Pharmacol. 2019;12:121-8. doi: 10.1080/17512433.2019.1570845.
20 Fukumura K, Yokota T, Baba Y, Arjona Ferreira JC. Phase 1, randomized, double-blind, placebo-controlled studies on the safety, tolerability, and pharmacokinetics of naldemedine in healthy volunteers. Clin Pharmacol Drug Dev. 2017;7:474-83. doi:10.1002/cpdd.387.
21 Webster LR, Yamada T, Arjona Ferreira JC. A phase 2b, randomized, double-blind placebo-controlled study to evaluate the efficacy and safety of naldemedine for the treatment of opioid-induced constipation in patients with chronic noncancer pain. Pain Med. 2017;18:2350-60. doi:10.1093/pm/pnw325.
22 Katakami N, Harada T, Murata T, Shinozaki K, Tsutsumi M, Yokota T, et al. Randomized phase III and extension studies: efficacy and impacts on quality of life of naldemedine in subjects with opioid-induced constipation and cancer. Ann. Oncol. 29 (2018) 1461-1467. doi: 10.1093/annonc/mdy118.
23 Nakajima A, Seki M, Taniguchi S, Ohta A, Gillberg PG, Mattsson JP, et al. Safety and efficacy of elobixibat for chronic constipation: results from a randomized, double-blinded, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial. Lancet Gastroenterol Hepatol. 2018;3:537-47. doi: 10.1016/S2468-1253
24 Marquis P, De La Loge C, Dubois D, McDermott A, Chassany O. Development and validation of the Patient Assessment of Constipation Quality of Life questionnaire. Scand J Gastroenterol. 2005; 40:540-51.
25 Mokhtare M, Ghafoori SM, Soltani-Kermanshahi M, Boghratian AH, Agah S, Sheikhvatan M. Reliability and validity of the Persian version of patient assessment of constipation- quality of life (JPAC-QOL) questionnaire. Gastroenterol Hepatol Bed Bench. 2017;10:289-94.
26 Ishihara M, Ikesue H, Matsunaga H, Suemaru K, Kitaichi K, Suetsugu K, et al. A multi-institutional study analyzing effect of prophylactic medication for prevention of opioid-induced gastrointestinal dysfunction. Clin J Pain. 2012;28:373-81. doi: 10.1097/ajp.0b013e318237d626.
27 Hatswell AJ, Vegter, S. Measuring quality of life in opioid-induced constipation: mapping EQ-5D-3 L and JPAC-QOL. Health Econ Rev. 2016;6:14. doi: 10.1186/s13561-016-0091-9.
28 C.L. Miles, D. Fellowes, Goodman, M.L. and Wilkinson, S. Laxatives for the management of constipation in palliative patients. Cochrane Database Syst. Rev. 4 (2006) CD003448. doi: 10.1002/14651858.cd003448.
29 Agra Y, Sacristá A, González, Ferrari M, Portugués A, Calvo MJ. Efficacy of senna versus lactulose in terminal cancer patients treated with opioids. J. Pain Symptom Manage. 1998;15:1-7. doi: 10.1016/S0885-3924(97)00276-5.